Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

DNLI

Denali Therapeutics Inc

Feb 13 • 04:00PM ET

18.77

-0.41 -2.14 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB REGN ALNY UTHR IONS MRNA SRPT NBIX VRTX PTCT

| Held by: VTI XBI IWM VB VBK VXF IWN IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-2.91	Insider Own	10.40%	Shs Outstand	146.63M	Perf Week	-10.96%
Market Cap	2.93B	Forward P/E	-	EPS next Y	-2.87	Insider Trans	-0.36%	Shs Float	139.92M	Perf Month	2.74%
Enterprise Value	2.13B	PEG	-	EPS next Q	-0.74	Inst Own	93.80%	Short Float	9.69%	Perf Quarter	7.13%
Income	-498.74M	P/S	-	EPS this Y	-15.13%	Inst Trans	4.01%	Short Ratio	8.31	Perf Half Y	29.81%
Sales	0.00M	P/B	2.97	EPS next Y	3.15%	ROA	-39.75%	Short Interest	13.56M	Perf YTD	13.69%
Book/sh	6.32	P/C	3.46	EPS next 5Y	-0.12%	ROE	-44.44%	52W High	23.77 -21.03%	Perf Year	-11.92%
Cash/sh	5.43	P/FCF	-	EPS past 3/5Y	-2.44% -4.46%	ROIC	-51.87%	52W Low	10.57 77.58%	Perf 3Y	-37.83%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.08% 7.05%	Perf 5Y	-72.20%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-5.30%	Oper. Margin	-	ATR (14)	1.30	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.79	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	44.38	Recom	1.06
Dividend Gr. 3/5Y	- -	Current Ratio	9.79	EPS Q/Q	-16.35%	SMA20	-7.66%	Beta	1.04	Target Price	32.86
Payout	-	Debt/Eq	0.05	Sales Q/Q	-	SMA50	0.48%	Rel Volume	0.81	Prev Close	19.18
Employees	422	LT Debt/Eq	0.04	Earnings	Nov 06 AMC	SMA200	17.95%	Avg Volume	1.63M	Price	18.77
IPO	Dec 08, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.03% -100.00%	Trades		Volume	1,314,688	Change	-2.14%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Resumed	UBS	Buy	$25
Apr-10-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Mar-07-25	Resumed	Morgan Stanley	Overweight	$41 → $33
Feb-11-25	Initiated	Deutsche Bank	Buy	$31
Jan-07-25	Initiated	Robert W. Baird	Outperform	$31
Jan-03-25	Initiated	William Blair	Outperform
Dec-16-24	Upgrade	Stifel	Hold → Buy	$37
Oct-10-24	Resumed	Raymond James	Mkt Perform
Oct-07-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-13-23	Initiated	Citigroup	Buy	$32
Nov-20-23	Resumed	JP Morgan	Overweight	$28
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$85 → $35
Sep-06-23	Initiated	B. Riley Securities	Buy	$38
Jan-30-23	Initiated	SVB Securities	Outperform	$50
Dec-05-22	Initiated	Cowen	Outperform
Nov-02-22	Upgrade	BTIG Research	Neutral → Buy	$38
Nov-02-22	Initiated	BofA Securities	Buy	$40
Jun-23-22	Initiated	Berenberg	Buy	$39
Dec-10-21	Resumed	Raymond James	Mkt Perform
Sep-21-21	Initiated	Oppenheimer	Outperform	$85

Show Previous Ratings

Feb-10-26 08:51AM	FDA Rejection Clouds Path For REGENXBIO's Rare Disease Treatment (Benzinga)
Feb-05-26 05:30PM	Denali Therapeutics Showcases ETV Data at WORLD: TIVI PDUFA Near, DNL126 Hits 80% CSF Drop (MarketBeat) -5.92% +5.29%
02:00PM	Denali Therapeutics Presents Enzyme TransportVehicle Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium (GlobeNewswire)
Feb-03-26 10:00AM	5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates (Zacks)
Feb-02-26 08:00AM	Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle Programs at the 2026 WORLDSymposium (GlobeNewswire)
04:00PM	Loading…
Jan-29-26 04:00PM	Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium (GlobeNewswire)
Jan-20-26 10:42AM	3 Biotech Stocks That Could Double In 2026 (24/7 Wall St.)
Jan-07-26 01:01PM	Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up (Zacks)
Jan-06-26 08:00AM	Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome (GlobeNewswire) +7.43%
Dec-30-25 08:00AM	The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) (GlobeNewswire)
Dec-29-25 09:13AM	3 Biotech Stocks With Major 2026 Catalysts (Zacks)
Dec-22-25 06:11AM	Is Denali Therapeutics (DNLI) the Most Promising Mid-Cap Healthcare Stock Under $50? (Insider Monkey)
Dec-10-25 04:58PM	Biggest Stock Movers Today, Dec. 10: PLAB, AVAV, & More (Motley Fool) -10.63%
12:14AM	Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Dec-09-25 04:01PM	Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
09:56AM	Loading…
Dec-05-25 09:56AM	Denali Enters Into a $275M Funding Deal With Royalty Pharma (Zacks)
05:00AM	Praxis soars higher; Bristol Myers CAR-T therapy wins broader use (BioPharma Dive)
Dec-04-25 07:00AM	Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement (GlobeNewswire) +5.84%
Nov-10-25 08:19PM	H.C. Wainwright Reiterates "Buy" Rating on Denali Therapeutics (DNLI) With $32 PT Following Q3 Results (Insider Monkey) +12.69%
Nov-07-25 01:23PM	DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug (Zacks)
Nov-06-25 04:01PM	Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
04:00PM	Denali Therapeutics Announces Board and Executive Leadership Updates (GlobeNewswire)
Oct-14-25 08:23AM	FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months (Zacks)
07:53AM	AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance (BioPharma Dive)
Oct-13-25 04:01PM	Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome) (GlobeNewswire)
Sep-10-25 11:30AM	Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report? (Zacks)
Aug-12-25 08:18AM	DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26 (Zacks) -5.03%
Aug-11-25 04:01PM	Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Aug-07-25 05:15AM	Clinical trial supply chains in the US navigate pharma tariffs (Clinical Trials Arena)
Aug-05-25 09:32AM	Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards? (Zacks)
11:58AM	Loading…
Jul-31-25 11:58AM	Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy (Insider Monkey)
Jul-30-25 08:55AM	Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue? (Zacks)
Jul-17-25 08:15AM	Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Companys Board of Directors (GlobeNewswire)
Jul-16-25 09:38AM	BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target (Insider Monkey)
Jul-08-25 09:59AM	DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review (Zacks)
Jul-07-25 08:00AM	Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II) (GlobeNewswire)
Jun-25-25 03:27AM	After myriad failures, a new wave of ALS drugs approaches (Pharma Voice)
Jun-05-25 11:30AM	Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report? (Zacks)
May-07-25 01:10PM	Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus (Zacks)
May-06-25 04:01PM	Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome (GlobeNewswire) -12.63%
May-05-25 09:13AM	5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates (Zacks)
May-02-25 01:20PM	Viatris Q1 Earnings Release: What's in Store for the Stock? (Zacks)
Apr-29-25 06:42AM	Can Amgen Keep the Beat Streak Alive This Earnings Season? (Zacks)
Apr-03-25 09:32AM	DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up (Zacks) -6.91%
Apr-02-25 08:00AM	Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program (GlobeNewswire) +11.80%
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-20-25 02:16PM	Denali Therapeutics: Vast Pipeline, First Approval Up Ahead (SeekingAlpha)
08:57AM	Why You Shouldn't Bet Against Denali (DNLI) Stock (Zacks)
Mar-04-25 08:00AM	Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer (TipRanks)
Mar-03-25 12:49PM	Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos Investments in 2025? (Insider Monkey) -8.21%
Feb-27-25 04:01PM	Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (GlobeNewswire) -10.97%
Feb-06-25 11:42AM	Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa (GlobeNewswire)
Jan-30-25 08:00AM	Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium (GlobeNewswire)
Jan-17-25 11:18AM	Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-13-25 08:00AM	Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases (GlobeNewswire)
Jan-08-25 08:00AM	Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) (GlobeNewswire)
07:25AM	Denali Therapeutics price target lowered to $32 from $35 at BTIG (TipRanks)
Jan-07-25 04:33PM	These Stocks Moved the Most Today: Nvidia, Micron, Aurora Innovation, Tesla, Carvana, Moderna, Palantir, and More (Barrons.com) +6.86%
04:08PM	Denali Reverses Its Fortunes With 'Too Early' Miss In ALS Treatment (Investor's Business Daily)
02:16PM	These Stocks Are Moving the Most Today: Nvidia, Micron, Aurora Innovation, Tesla, Carvana, Moderna, Palantir, and More (Barrons.com)
12:48PM	Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected (Benzinga)
10:13AM	Denali Therapeutics Phase II/III trial of ALS therapy fails to meet primary endpoint (Clinical Trials Arena)
10:13AM	Denali Therapeutics ALS therapy fails to meet primary endpoint in Phase II/III trial (Clinical Trials Arena)
09:33AM	Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet. (Investor's Business Daily)
04:41AM	ALS drugs from Denali, Calico come up short, marking setback for Healey trial (BioPharma Dive)
Jan-06-25 04:30PM	Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial (GlobeNewswire) -6.77%
Jan-03-25 01:08PM	Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic (Benzinga)
Dec-17-24 06:25AM	Denali Therapeutics upgraded to Buy from Hold at Stifel (TipRanks)
Dec-06-24 11:31AM	Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report? (Zacks) +6.73%
Dec-05-24 08:00AM	Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease (GlobeNewswire)
Nov-06-24 04:01PM	Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) +6.87%
Oct-29-24 10:01AM	Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-13-24 04:56PM	Denali Therapeutics Inc. (DNLI): Jeff Bezos Is Buying This Stock Now (Insider Monkey)
Sep-16-24 11:22AM	Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength? (Zacks)
Sep-04-24 08:15AM	High-dose Spinraza meets study goal; Top Dyne executives exit (BioPharma Dive)
Sep-03-24 08:00AM	Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome) (GlobeNewswire)
Aug-19-24 10:13AM	Genetic testing in Parkinsons disease patients: a standard of care imperative? (Medical Device Network)
Aug-14-24 02:00PM	Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration (GlobeNewswire)
Aug-06-24 09:55AM	Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to Trade (Zacks)
Aug-01-24 06:45AM	Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Jul-23-24 06:13AM	Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar? (Zacks)
Jul-16-24 03:19PM	Denali Therapeutics Stock Gets Technical Rating Upgrade (Investor's Business Daily)
Jul-08-24 07:09PM	3 Longevity Stocks to Buy for Anti-Aging Breakthroughs (InvestorPlace)
Jun-28-24 08:37AM	Denali (DNLI) Outperforms Industry in 3 Months: Here's Why (Zacks)
Jun-24-24 09:07AM	Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last? (Zacks)
Jun-12-24 07:00AM	Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer (PR Newswire)
Jun-06-24 11:31AM	Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report? (Zacks)
Jun-04-24 01:17PM	Denali's (DNLI) Candidate Selected for FDA's START Pilot Program (Zacks)
Jun-03-24 08:00AM	Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies (GlobeNewswire) +9.81%
May-09-24 07:00AM	Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management (PR Newswire)
May-08-24 11:17AM	Stifel Adjusts Price Target on Denali Therapeutics to $22 From $26, Maintains Hold Rating (MT Newswires) +12.17%
09:16AM	Wedbush Adjusts Denali Therapeutics' Price Target to $30 From $31, Keeps Outperform Rating (MT Newswires)
08:20AM	Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus (Zacks)
May-07-24 10:56PM	DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
05:56PM	Denali Therapeutics Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic Shifts (GuruFocus.com)
04:01PM	Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
May-01-24 08:00AM	Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial (GlobeNewswire)
Apr-09-24 08:46AM	Why Denali Therapeutics (DNLI) Stock Might be a Great Pick (Zacks)
Apr-08-24 08:00AM	Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences (PR Newswire)
Mar-28-24 11:30AM	Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report? (Zacks)

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CAROLE HO	Former Affiliate	Feb 05 '26	Proposed Sale	20.29	39,490	801,394		Feb 05 04:14 PM
CAROLE HO	Former Affiliate	Feb 04 '26	Proposed Sale	21.18	150,000	3,176,970		Feb 04 04:16 PM
CAROLE HO	Former Affiliate	Feb 03 '26	Proposed Sale	22.16	150,000	3,324,060		Feb 03 04:47 PM
Watts Ryan J.	President and CEO	Jan 06 '26	Sale	16.50	35,198	580,767	296,833	Jan 08 04:20 PM
Schuth Alexander O.	COFO and Secretary	Jan 06 '26	Sale	16.50	17,218	284,097	282,828	Jan 08 04:19 PM
Ho Carole	Consultant	Jan 06 '26	Proposed Sale	16.50	17,218	284,097		Jan 06 08:28 PM
Schuth Alexander O.	Officer	Jan 06 '26	Proposed Sale	16.50	17,218	284,097		Jan 06 08:25 PM
Watts Ryan J.	Director	Jan 06 '26	Proposed Sale	16.50	35,198	580,767		Jan 06 08:24 PM
CAROLE HO	Officer	Dec 04 '25	Proposed Sale	19.00	1,882	35,758		Dec 04 04:41 PM
Schuth Alexander O.	COFO and Secretary	Aug 12 '25	Sale	13.58	2,937	39,884	242,346	Aug 14 08:33 PM
Ho Carole	Chief Medical Officer	Aug 12 '25	Sale	13.58	2,937	39,884	217,391	Aug 14 08:33 PM
Ho Carole	Chief Medical Officer	Aug 13 '25	Sale	14.64	806	11,800	216,585	Aug 14 08:33 PM
CAROLE HO	Officer	Aug 13 '25	Proposed Sale	13.22	806	10,655		Aug 13 04:45 PM
Schuth Alexander O.	Officer	Aug 12 '25	Proposed Sale	13.58	2,937	39,876		Aug 12 08:46 PM
Ho Carole	Officer	Aug 12 '25	Proposed Sale	13.58	2,937	39,876		Aug 12 08:44 PM
Ho Carole	Chief Medical Officer	Aug 05 '25	Option Exercise	0.68	44,655	30,365	220,328	Aug 07 05:34 PM
Watts Ryan J.	President and CEO	Jul 09 '25	Option Exercise	1.05	495,282	520,792	748,353	Jul 11 05:13 PM
Watts Ryan J.	President and CEO	Jul 09 '25	Sale	15.00	495,282	7,429,230	253,071	Jul 11 05:13 PM
Watts Ryan J.	Officer	Jul 09 '25	Proposed Sale	14.33	495,282	7,097,391		Jul 09 04:13 PM

Open in Screener

REGN

Regeneron Pharmaceuticals, Inc

Feb 13 • 04:00PM ET

803.17

+19.52 2.49 %

Healthcare • Biotechnology • USA • NASD

REGN Regeneron Pharmaceuticals, Inc daily Stock Chart

Peers: AMGN BIIB GILD VRTX MRNA BMRN INCY EXEL IONS

| Held by: VTI VOO QQQ IVV SPY VTV IBB XLV JEPI QQQM

Index	NDX, S&P 500	P/E	19.32	EPS (ttm)	41.56	Insider Own	3.74%	Shs Outstand	103.90M	Perf Week	2.25%
Market Cap	84.90B	Forward P/E	15.24	EPS next Y	52.71	Insider Trans	-0.29%	Shs Float	101.75M	Perf Month	6.50%
Enterprise Value	79.26B	PEG	1.38	EPS next Q	9.16	Inst Own	84.57%	Short Float	2.14%	Perf Quarter	17.82%
Income	4.50B	P/S	5.92	EPS this Y	2.30%	Inst Trans	-0.61%	Short Ratio	2.28	Perf Half Y	41.91%
Sales	14.34B	P/B	2.72	EPS next Y	16.29%	ROA	11.49%	Short Interest	2.18M	Perf YTD	4.06%
Book/sh	295.71	P/C	9.86	EPS next 5Y	11.05%	ROE	14.87%	52W High	821.11 -2.18%	Perf Year	19.12%
Cash/sh	81.46	P/FCF	20.81	EPS past 3/5Y	2.76% 6.33%	ROIC	13.18%	52W Low	476.49 68.56%	Perf 3Y	5.13%
Dividend Est.	2.65 (0.33%)	EV/EBITDA	18.67	Sales past 3/5Y	5.62% 11.04%	Gross Margin	81.56%	Volatility	3.21% 2.95%	Perf 5Y	65.39%
Dividend TTM	3.52 (0.44%)	EV/Sales	5.53	EPS Y/Y TTM	5.49%	Oper. Margin	25.81%	ATR (14)	23.29	Perf 10Y	111.91%
Dividend Ex-Date	Feb 20, 2026	Quick Ratio	3.39	Sales Y/Y TTM	0.99%	Profit Margin	31.41%	RSI (14)	61.64	Recom	1.69
Dividend Gr. 3/5Y	- -	Current Ratio	4.13	EPS Q/Q	-2.57%	SMA20	5.38%	Beta	0.40	Target Price	875.67
Payout	8.49%	Debt/Eq	0.10	Sales Q/Q	2.51%	SMA50	5.70%	Rel Volume	1.02	Prev Close	783.65
Employees	15410	LT Debt/Eq	0.09	Earnings	Jan 30 BMO	SMA200	27.84%	Avg Volume	955.45K	Price	803.17
IPO	Apr 02, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.56% 1.93%	Trades		Volume	974,624	Change	2.49%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Upgrade	BofA Securities	Underperform → Buy	$860
Dec-03-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$767
Nov-24-25	Resumed	Truist	Buy	$798
Nov-24-25	Initiated	HSBC Securities	Buy	$255
Nov-13-25	Initiated	Scotiabank	Sector Perform	$650
Aug-14-25	Initiated	Rothschild & Co Redburn	Buy	$890
Jun-30-25	Downgrade	Argus	Buy → Hold
May-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$580
May-30-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$662
May-14-25	Upgrade	Citigroup	Neutral → Buy	$700
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight	$695
Feb-05-25	Upgrade	Leerink Partners	Market Perform → Outperform	$762 → $834
Jan-16-25	Downgrade	UBS	Buy → Neutral	$1130 → $738
Dec-10-24	Resumed	BofA Securities	Underperform	$565
Nov-15-24	Initiated	Wolfe Research	Outperform	$1150
Nov-14-24	Initiated	Citigroup	Neutral	$895
Sep-24-24	Downgrade	Leerink Partners	Outperform → Market Perform	$1175 → $1077
Mar-12-24	Initiated	Bernstein	Outperform	$1125
Jan-12-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$884 → $1076
Nov-09-23	Initiated	Deutsche Bank	Hold	$800

Show Previous Ratings

Today 01:45PM	CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens (Benzinga)
10:23AM	Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
09:57AM	Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts? (Insider Monkey)
08:23AM	Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors (Benzinga)
Feb-12-26 11:39PM	1 Healthcare Stock Worth Your Attention and 2 Facing Challenges (StockStory)
11:08AM	Loading…
11:08AM	Sanofi Shares Fall After CEO Change (The Wall Street Journal)
09:44AM	Sanofi Tumbles After Board Shockingly Ousts CEO Paul Hudson (Investor's Business Daily)
09:30AM	Will Eylea Sales Decline Weigh on REGN's Top Line in 2026? (Zacks)
Feb-11-26 04:05PM	Regeneron Announces Investor Conference Presentations (GlobeNewswire)
04:56AM	The Zacks Analyst Blog Highlights NVIDIA, Amazon.com, Regeneron, National Presto and AXIL (Zacks)
04:33AM	Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill (BioPharma Dive)
Feb-10-26 04:14PM	Top Stock Reports for NVIDIA, Amazon & Regeneron (Zacks)
04:07PM	Has Dupixent Met Its Match? Rivals Nektar, Evommune Catapult On Eczema Results. (Investor's Business Daily)
09:07AM	Evommune Nearly Doubles Has Dupixent Met Its Match In Eczema? (Investor's Business Daily)
07:13AM	Nektar, continuing comeback, says eczema drugs effects hold up in follow-up study (BioPharma Dive)
07:00AM	Loading…
07:00AM	Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy (GlobeNewswire)
Feb-06-26 09:26AM	Have originator medicines list prices started to drop in the US? (Pharmaceutical Technology)
Feb-05-26 04:17PM	TrumpRx's launch is hours away. Here's why it may not lower drug prices for most Americans. (MarketWatch)
12:48PM	Cardinal Health Stock Jumps After Earnings. Its CEO Explains What Went Right. (Barrons.com)
Feb-04-26 07:27PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
12:27PM	Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory (Insider Monkey)
Feb-03-26 10:43AM	NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study (Zacks)
09:27AM	Here's Why Gilead Sciences Stock Surged 21% in a Month (Zacks)
Feb-02-26 06:08PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
07:00AM	EYLEA HD (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases (GlobeNewswire)
Jan-31-26 04:37PM	Regeneron (REGN) Draws Higher Target From TD Cowen (Insider Monkey)
12:35PM	Regeneron Pharmaceuticals, Inc. (REGN) Posts Q4 Earnings Beat, EPS Shines (Insider Monkey)
Jan-30-26 04:09PM	Regeneron Falls, But Hints That It Could Be Ready To Flex Its Dealmaking Muscles (Investor's Business Daily)
04:02PM	Regeneron Pharmaceuticals Inc (REGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
11:28AM	Regeneron Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
11:15AM	Loading…
11:15AM	Dow Jones Leader Amgen Leads These Biotech Stocks Heading Into Q4 Earnings Season (Investor's Business Daily)
10:56AM	Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory (Benzinga)
10:30AM	Regeneron (REGN) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
10:25AM	REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth (Zacks)
10:22AM	Regeneron Yo-Yos, But Hints That It Could Be Ready To Flex Its Dealmaking Muscles (Investor's Business Daily)
10:11AM	KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate (Zacks)
07:56AM	Sanofi touts strong new launch sales amid looming Dupixent patent expiry (Pharmaceutical Technology)
07:40AM	Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates (Zacks)
06:47AM	Regeneron: Q4 Earnings Snapshot (Associated Press Finance)
06:40AM	Regeneron (NASDAQ:REGN) Posts Better-Than-Expected Sales In Q4 CY2025 (StockStory)
06:30AM	Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results (GlobeNewswire)
04:19AM	Oil Earnings, Inflation Data, Likely Fed Chair Decision: Still to Come This Week (The Wall Street Journal)
Jan-29-26 05:22PM	Analyst Report: Sanofi (Morningstar Research)
12:09PM	Sanofi Edges Higher As Immunology Powerhouse, Dupixent, Wallops Forecasts (Investor's Business Daily)
11:21AM	Sanofi Beats on Q4 Earnings, Expects Profitable Growth in 2026 (Zacks)
08:53AM	Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status (Zacks)
08:21AM	Evercore ISI Highlights Dupixent and Eylea HD as Key Growth Drivers For Regeneron Pharmaceuticals, Inc. (REGN) (Insider Monkey)
08:20AM	PINKs 58% Gains Since 2021 Come From Picking Winners, Not Owning Everything (24/7 Wall St.)
03:54AM	Apple, Oil Earnings, Inflation Data: Still to Come This Week (The Wall Street Journal)
Jan-28-26 10:03PM	Earnings To Watch: Regeneron (REGN) Reports Q4 Results Tomorrow (StockStory)
11:24AM	Amgen Set to Report Q4 Earnings: What Investors Should Know (Zacks)
09:45AM	NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold (Zacks)
09:11AM	Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings? (Zacks)
Jan-27-26 12:15PM	Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why (Zacks)
09:46AM	Regeneron (REGN) Posted Solid Q3 Results, Eyes 2026 Pipeline Catalysts (Insider Monkey)
Jan-26-26 10:00AM	Will Twist Bioscience (TWST) Report Negative Earnings Next Week? What You Should Know (Zacks)
08:20AM	Tesla, Microsoft, Meta, SanDisk And More: Stocks With Earnings This Week (Benzinga)
Jan-25-26 07:52AM	Big Tech earnings, Fed meeting feature as markets end January with busiest week of Q1: What to watch (Yahoo Finance)
04:46AM	Here Are the Top Four Blue-Chip Stocks To Buy in 2026, According to WarrenAI (Investing.com)
Jan-23-26 07:00PM	Mag 7 earnings, Fed's rate decision: What to Watch (Yahoo Finance Video)
11:40AM	REGN or ILMN: Which Is the Better Value Stock Right Now? (Zacks)
10:00AM	Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jan-22-26 08:47PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
01:25PM	2 Healthcare Stocks Poised for a Comeback in 2026 (Motley Fool)
08:55AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Jan-21-26 12:00PM	Nation's Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search (GlobeNewswire)
06:39AM	Corvus shares nearly triple on positive data for eczema pill (BioPharma Dive)
Jan-20-26 08:36AM	Bayer Shares Jump as Supreme Court Agrees to Review Key Roundup Case (Zacks)
08:28AM	Should You Be Excited for Regeneron (REGN)? (Insider Monkey)
Jan-19-26 03:23PM	Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All (MarketBeat)
Jan-15-26 10:56AM	JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death (Clinical Trials Arena)
08:32AM	ANIP Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
Jan-14-26 02:05PM	JPM26: Regeneron will not overpay in M&A deals amid lead asset patent expiries (Pharmaceutical Technology)
12:25PM	Humana Partners With Atlas to Enhance Cancer Care for Seniors (Zacks)
Jan-13-26 03:22PM	Regeneron's Yancopoulos on Hearing Loss Gene Therapy, Weight Loss Drugs (Bloomberg)
12:57PM	AbbVie Signs US Deal to Cut Drug Prices, Secure Tariff Exemptions (GuruFocus.com)
Jan-12-26 08:55AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Jan-11-26 08:31PM	A big Wall Street flip just changed the Regeneron narrative (TheStreet)
Jan-09-26 04:52PM	Top Research Reports for NVIDIA, Alphabet & Amazon.com (Zacks)
12:00PM	Regeneron (REGN) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Jan-08-26 09:28AM	Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower (Benzinga)
Jan-07-26 04:18PM	Regeneron Just Moved From Underperform To Buy - Here's Why (Benzinga)
04:05PM	Regeneron Stock Lagged Behind the S&P 500 Last Year. Why This Firm Moved Off the Sidelines. (Barrons.com)
12:10PM	Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? (Zacks)
11:40AM	REGN vs. ILMN: Which Stock Is the Better Value Option? (Zacks)
11:20AM	Why Regeneron (REGN) Stock Is Trading Up Today (StockStory)
09:41AM	Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly)
07:37AM	BofA double-upgrades Regeneron, citing stronger Eylea outlook and 2026 catalysts (Investing.com)
Jan-06-26 11:40AM	REGN vs. ILMN: Which Stock Should Value Investors Buy Now? (Zacks)
08:55AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
07:18AM	Regeneron Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know (Barchart)
05:30AM	Big Pharma Has More Going for It Than Obesity Drugs (The Wall Street Journal)
04:40AM	The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson (Zacks)
Jan-05-26 01:45PM	KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? (Zacks)
10:58AM	Intellia Stock Declines Around 55% in 3 Months: Here's Why (Zacks)
07:41AM	Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026 (Zacks)
Jan-02-26 04:05PM	Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026 (GlobeNewswire)
09:53AM	Will ANIP's Rare Disease Franchise Maintain Momentum in 2026? (Zacks)
08:40AM	REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? (Zacks)
Dec-31-25 08:10AM	BAYRY's 2025 Revival: Will the Momentum Continue in 2026? (Zacks)

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pitofsky Jason	SVP Controller	Feb 09 '26	Option Exercise	492.00	1,000	492,000	6,308	Feb 11 04:03 PM
Pitofsky Jason	SVP Controller	Feb 09 '26	Sale	778.52	2,036	1,585,058	4,272	Feb 11 04:03 PM
RYAN ARTHUR F	Director	Feb 09 '26	Sale	778.53	100	77,853	17,803	Feb 11 04:02 PM
Arthur F. Ryan	Director	Feb 09 '26	Proposed Sale	785.51	400	314,204		Feb 09 05:02 PM
Pitofsky Jason	Officer	Feb 09 '26	Proposed Sale	783.17	2,036	1,594,534		Feb 09 04:03 PM
Bassler Bonnie L	Director	Jan 07 '26	Option Exercise	374.12	1,500	561,180	3,203	Jan 08 04:03 PM
Bassler Bonnie L	Director	Jan 07 '26	Sale	800.00	1,500	1,200,000	1,703	Jan 08 04:03 PM
Bassler Bonnie L	Director	Jan 07 '26	Proposed Sale	800.00	1,500	1,200,000		Jan 07 12:03 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	Dec 31 '25	Option Exercise	0.00	28,570	0	339,030	Jan 05 05:54 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Dec 31 '25	Option Exercise	0.00	28,570	0	243,093	Jan 05 05:53 PM
SING GEORGE L	Director	Dec 30 '25	Option Exercise	520.01	9,212	4,790,332	37,040	Dec 31 05:05 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	Dec 09 '25	Option Exercise	555.67	146,815	81,580,691	442,334	Dec 11 04:27 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Dec 09 '25	Option Exercise	555.67	172,723	95,976,989	369,668	Dec 11 04:23 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Nov 20 '25	Option Exercise	555.67	14,450	8,029,431	35,525	Nov 24 04:07 PM
Bassler Bonnie L	Director	Nov 20 '25	Option Exercise	371.40	760	282,264	2,308	Nov 24 04:05 PM
Bassler Bonnie L	Director	Nov 20 '25	Sale	750.00	760	570,000	1,548	Nov 24 04:05 PM
Bassler Bonnie L	Director	Nov 20 '25	Proposed Sale	750.00	760	570,000		Nov 20 02:31 PM
Pitofsky Jason	VP Controller	Nov 07 '25	Sale	651.43	431	280,766	4,233	Nov 10 04:37 PM
Jason Pitofsky	Officer	Nov 07 '25	Proposed Sale	651.00	431	280,581		Nov 07 05:06 PM
POON CHRISTINE A	Director	Oct 29 '25	Option Exercise	520.01	6,500	3,380,065	8,852	Oct 31 04:09 PM
POON CHRISTINE A	Director	Oct 30 '25	Option Exercise	520.01	2,712	1,410,267	5,064	Oct 31 04:09 PM
POON CHRISTINE A	Director	Oct 29 '25	Sale	654.27	6,500	4,252,745	2,352	Oct 31 04:09 PM
MURPHY ANDREW J	EVP Research	Oct 29 '25	Option Exercise	555.67	35,000	19,448,450	84,074	Oct 31 04:06 PM
Christine Poon	Director	Oct 29 '25	Proposed Sale	652.91	6,500	4,243,915		Oct 29 04:36 PM

DNLI

Denali Therapeutics Inc

REGN

Regeneron Pharmaceuticals, Inc

Upgrade your FINVIZ experience